Cargando…
Novel Agents as Main Drivers for Continued Improvement in Survival in Multiple Myeloma
SIMPLE SUMMARY: Survival of patients with multiple myeloma continues to improve over time in parallel with the development of new treatments. The combination of novel agents in the first-line setting appears to be the main factor driving improvement, resulting in overall survival (OS) of more than 1...
Autores principales: | Puertas, Borja, González-Calle, Verónica, Sobejano-Fuertes, Eduardo, Escalante, Fernando, Queizán, José A., Bárez, Abelardo, Labrador, Jorge, Alonso-Alonso, José María, García de Coca, Alfonso, Cantalapiedra, Alberto, Villaescusa, Teresa, Aguilar-Franco, Carlos, Alejo-Alonso, Elena, Rey-Bua, Beatriz, López-Corral, Lucía, García-Sanz, Ramón, Puig, Noemi, Gutiérrez, Norma C., Mateos, María-Victoria |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10000382/ https://www.ncbi.nlm.nih.gov/pubmed/36900349 http://dx.doi.org/10.3390/cancers15051558 |
Ejemplares similares
-
Multiple myeloma with t(11;14): impact of novel agents on outcome
por: Puertas, Borja, et al.
Publicado: (2023) -
PB2102: IMPACT OF AUTOLOGOUS STEM CELL TRASPLANTATION IN AL AMYLOIDOSIS. EXPERIENCE IN A SINGLE TERTIARY HOSPITAL
por: Alonso, Elena Alejo, et al.
Publicado: (2023) -
Recovery of polyclonal immunoglobulins one year after autologous stem cell transplantation as a long-term predictor marker of progression and survival in multiple myeloma
por: González-Calle, Verónica, et al.
Publicado: (2017) -
Drug-induced Thrombotic Microangiopathy During Maintenance Treatment in a Patient With Multiple Myeloma
por: Higuero Saavedra, Víctor, et al.
Publicado: (2019) -
Anti-BCMA CAR T-cell Therapy: Changing the Natural History of Multiple Myeloma
por: Puertas, Borja, et al.
Publicado: (2022)